Cat.#: ASSD-135
Description | JC-1 is a Mitochondrial membrane potential indicator/dye that is widely used in apoptosis studies to monitor mitochondrial health. The product is used as an indicator of mitochondrial membrane potential in neurons and also intact tissues and isolated mitochondria, allowing both qualitative visualization and quantitative detection. Interpretation of Results • At low concentrations (due to low mitochondrial membrane potential), JC-1 is predominantly a monomer that yields green fluorescence with emission of 530±15 nm. • At high concentrations (due to high mitochondrial membrane potential), the dye aggregates yielding a red to orange colored emission (590±17.5 nm). Depolarization is indicated by a decrease the aggregate fluorescent count and hyperpolarization is indicated by an increase. |
Size | 5 mg |
Chemical Name | 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide |
Molecule Weight | 652.2 |
Molecular formula | C25H27Cl4IN4 |
Purity | >95% |
Storage | Store at -20° C |
Shipping | Shipped at 4°C |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-104 | Hoechst 33258 (AC104) | 25 mg, 100 mg | inquiry |
ASSD-213 | Fluorescein 6-Maleimide (AC213) | 25 mg, 250 mg | inquiry |
ASSD-110 | Picro Sirius Red Stain Kit (AC110) | 1 kit, 100 tests | inquiry |
ASSD-205 | Acridinium C2 NHS Ester (AC205) | 5 mg, 10 mg | inquiry |
ASSD-125 | Fluorescent D1 antagonist [SKF83566-green] (AC125) | 50 μg | inquiry |
ASSD-165 | FLUO 3-AM (AC165) | 1 mg | inquiry |
ASSD-216 | K 114 (AC216) | 10 mg, 50 mg | inquiry |
ASSD-155 | Bromophenol blue (AC155) | 5g | inquiry |
ASSD-224 | Antifade Fluorescence Mounting Medium with DAPI (aqueous) (AC224) | 10 mL | inquiry |
ASSD-105 | Hoechst 33342 (AC105) | 10 mg, 100 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.